FDA lowers patient age for hepatitis A vaccine

Merck & Co. on Monday said US regulators have approved its already marketed Hepatitis A Vaccine Inactivated for use in children as young as 12 months old; the minimum age had been least two years old.

The Vaqta vaccine is used to prevent infection with Hepatitis A, a virus that children sometimes pick up without developing symptoms and pass on to their siblings and other children.

Although the source of hepatitis A is not known in nearly half of all cases, it tends to be spread by oral contact with fecal matter and ingestion of contaminated food or water. There were an estimated 8,800 reported cases of hepatitis A in the United States during 2002, the drugmaker said.

Print Version
Tell-a-Friend comments powered by Disqus

RELATED ARTICLES:

New biomarkers may influence drug design and alternative treatments of cancer, study shows   UGA ecologist finds another cause of antibiotic resistance   New drug for neuroblastoma shows promise in phase I study   Baclofen shows promise in patients with alcohol-induced liver disease   Findings point to an ‘off switch’ for drug resistance in cancer   Stopping statins may benefit terminally ill patients   Cholesterol drug users may use pills as a license to overeat   Pfizer lung cancer drug beats chemo for previously untreated patients   Mass. General study identifies path to safer drugs for heart disease, cancer   Gates Foundation awards Notre Dame $23 million for malaria, dengue studies   Cancer drug protects against diabetes   Malaria drug target raises hopes for new treatments